Alosetron in Irritable Bowel Syndrome: Strategies for its Use in a Common Gastrointestinal Disorder

By Lembo A.  

Drugs, Vol. 63, Iss. 18, 2003-01 ,pp. : 1895-1905

Adis International

Access to resources Recommend Favorite

Reassessing the Benefits and Risks of Alosetron: What is its Place in the Treatment of Irritable Bowel Syndrome?

By Andresen V.  

Drug Safety, Vol. 27, Iss. 5, 2004-01 ,pp. : 283-292

Adis International

Access to resources Recommend Favorite

Alosetron Reduces Time Lost from Work in Women with Diarrhoea-Predominant Irritable Bowel Syndrome: Data from Phase III Placebo-Controlled Clinical Trials

By Jhingran P.   decker C.   Watson M.   Northcutt A.   Ricci J-F.  

Clinical Drug Investigation, Vol. 21, Iss. 12, 2001-12 ,pp. : 843-852

Adis International

Access to resources Recommend Favorite

Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

By Lynd Larry D.   Najafzadeh Mehdi   Colley Lindsey   Byrne Michael F.   Willan Andrew R.   Sculpher Mark J.   Johnson F. Reed   Hauber A. Brett  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 411-417

Blackwell Publishing

Access to resources Recommend Favorite

Irritable Bowel Syndrome

By Spinelli Antonella  

Clinical Drug Investigation, Vol. 27, Iss. 1, 2007-01 ,pp. : 15-33

Adis International

Access to resources Recommend Favorite